Loading
A phase 3 trial of Tafasitamab, Rituximab, Lenalidomide in follicular lymphoma, run by Incyte Corporation, active and no longer recruiting.
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. is a phase 3 interventional study registered as NCT04680052 by Incyte Corporation, with 654 participants enrolled, started 2021-04-15 and due to reach its primary completion in 2024-02-23. Interventions recorded: tafasitamab, rituximab, lenalidomide, placebo. Conditions listed: Follicular Lymphoma, Marginal Zone Lymphoma. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
654 enrolled.
95% CI 19.22 to NA; Figures from the ClinicalTrials.gov results section (first posted 2025-04-04), not from a publication · 95% CI 11.53 to 16.39
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| FL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred Firstprimary | FL: Tafasitamab + Rituximab + Lenalidomide | 273 | 22.37 months | - | - | link |
| FL: Placebo + Rituximab + Lenalidomide | 275 | 13.93 months |
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Tafasitamab, Incyte, Lenalidomide, PROTACs & molecular glues (targeted protein degradation).
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Tafasitamab, Incyte, Lenalidomide, Monoclonal antibodies.
Shares Marginal zone lymphoma, Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Rituximab, Follicular lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/